芪归益肾方治疗慢性肾脏病脾肾两虚证的临床研究
Study on the Curative Effect of Qigui Yishen Decoction in the Treatment of Patients with Chronic Kidney Diseases of Spleen and Kidney Deficiency
-
摘要: 目的 探讨芪归益肾方治疗慢性肾脏病,对脾肾两虚证患者的临床疗效。方法 将符合诊断的慢性肾脏病患者进行分组治疗,均给予优质低蛋白、低盐、低脂、低磷饮食,并纠正水电解质紊乱、酸中毒、贫血、降压、抗凝、调节血脂等基础治疗。治疗组在此基础上口服芪归益肾方。4周后观察肾功能、血清纤溶酶原激活物抑制剂-1(PAI-1)、转化生长因子-β1(TGF-β1)及中医证候积分等客观指标进行评价。结果 2组治疗后中医证候积分比治疗前明显降低(P<0.05~0.01),治疗组优于对照组(P<0.05~0.01);治疗后2组PAI-1、ALB/Cr、TGF-β1、IL-6水平明显降低(P<0.05~0.01),治疗组优于对照组(P<0.05~0.01)。结论 芪归益肾方在保护肾功能和减轻肾脏纤维化进展等方面疗效确切,其治疗作用可能与改善患者凝血以及内皮细胞功能相关。Abstract: OBJECTIVE To study the clinical curative effect of Qigui Yishen decoction in the treatment of patients with chronic kidney diseases of spleen and kidney deficiency.METHODS Patients with chronic kidney diseases met the diagnosis criteria were divided into two groups. Both groups were given the high quality low protein, low salt, low fat, low phosphorus diet, and also given basic treatments such as correcting water and electrolyte disorders, acidosis, anemia, lowering blood pressure, anticoagulation and regulating lipid. On the basis of this, the treatment group was also given Qigui Yishen decoction orally. Objective indexes including kidney function,serum plasminogen activator inhibitor-1 (PAI-1), transforming growth factor-β1 (TGF-β1) and changes of TCM syndrome scores were observed after four weeks. RESULTS After the treatment, TCM syndrome scores in two groups decreased significantly compared with pre-treatment (P<0.05~0.01), and the treatment group was better than the control group (P<0.05~0.01). PAI-1, ALB/Cr, TGF-β1 and IL-6 levels in two groups decreased significantly after treatment (P<0.05~0.01), and the treatment group was better the control group (P<0.05~0.01). CONCLUSIONS Qigui Yishen decoction has definite curative effect on protecting renal function and alleviating the progress of renal fibrosis, and its therapeutic effect may be related to the improvement of blood coagulation and endothelial cell function.